Peter Voorhees, MD, Atrium Health

Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

April 7th 2025

Experts discuss when physicians should consider referring patients to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (R/R MM). They emphasize the importance of early referral and access to CAR T in earlier lines of therapy while commenting on the similarities and differences in referral timing, particularly for patients treated in the community.

Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

April 7th 2025

Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.

Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

March 31st 2025

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

March 31st 2025

Experts discuss where chimeric antigen receptor (CAR) T-cell therapy currently fits in the treatment paradigm, highlighting the patient factors and disease characteristics that influence its use in clinical decision-making.

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

November 2nd 2022

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th 2021

Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

December 7th 2020

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

July 17th 2020

MRD Monitoring in Multiple Myeloma

July 17th 2020